PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
Recruiting · Phase 1 · NCT04837547
Conditions: Neuroblastoma, Diffuse Intrinsic Pontine Glioma
At a glance
- Research payments reported, 2025
- $2,600
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- University of Florida (with Beat Childhood Cancer Research Consortium)
- Tested
- Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) (biological)
- Dates
- Started 2021-09-20; completion 2032-09
- Results posted
- Not yet
A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)).
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Caris Mpi, Inc. reported $2,600 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Pennsylvania State University $2,600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.